Indian Overseas Bank Regulatory Approval

Indian Overseas Bank Management Change

Indian Overseas Bank's board appointed Mr. Akshit Choudhary as Chief Financial Officer effective 1 November 2026, replacing Mr. Madhaw Chandra Jha. The filing includes his brief profile and the required LODR disclosures.

Indian Overseas Bank Investor Presentation: Key Takeaways

Q2 FY27 net profit Rs1,912 Cr, up 55.95% YoY and 15.25% QoQ. NII Rs3,867 Cr (+26.41% YoY). ROE 24.58%, ROA 1.53%, GNPA 1.19%.

Indian Overseas Bank Results Update

IOB's net profit jumped 55.95% YoY to ₹1,912 Crore in Q2 FY27, with operating profit rising 25.67% to ₹3,016 Crore. NII grew 26.41% and NPA ratios continued to improve.

Indian Overseas Bank Q2 FY27 Results: Net Profit ₹1,963 Cr, Up 55.9% YoY

Indian Overseas Bank reported revenue from operations of ₹9,201 Cr (+17.2% YoY) and net profit of ₹1,963 Cr (+55.9% YoY) for Q2 FY27.

Key figure

Net profit ₹1,963 Cr · +55.9% YoY

Indian Overseas Bank Business Update

Indian Overseas Bank disclosed RBI findings on understated risk weights for some exposures. It states no net profit impact, with CRAR remaining well above minimums.

Indian Overseas Bank Other Announcement

The filing presents the shareholding pattern of Indian Overseas Bank for the quarter ended September 30, 2026. No material transaction is reported.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.